,,iii  #aai? ,,congress  #b;d ,session  
,s4 ,,res4 #fbj  ,,9 ,,! ,,s5ate ,,( ,,!
 ,,unit$ ,,/ates  ,febru>y #bf1         
#bjbf,mr4 ,b>rasso 7= himself & ,mr4    
,blum5?al7 submitt$ ! foll[+ resolution2
 :i* 0 consid]$ & agre$ to  ,,resolution
  ,designat+ ,febru>y #bh1 #bjbf1 z ,r>e
 ,disease ,day4  ,:]eas a r>e disease or
 disord] is a disease or disord] t      
affects a small numb] ( pati5ts2 ,:]eas1
 9 ! ,unit$ ,/ates1 a r>e disease or    
disord] is def9$ z affect+ few] ?an     
#bjj1jjj individuals2 ,:]eas1 z ( ! date
 ( adoption ( ?is resolution1 m ?an     
#cj1jjj1jjj individuals 9 ! ,unit$      
,/ates are liv+ ) at lea/ #a ( ! m ?an  
#aj1jjj kn[n r>e diseases or disord]s2  
,:]eas *ildr5 ) r>e diseases or disord]s
 acc\nt = a significant portion ( !     
population affect$ by r>e diseases or   
disord]s 9 ! ,unit$ ,/ates2 ,:]eas _m   
r>e diseases & disord]s are s]i\s &     
life-?reat5+2 ,:]eas f9anc+ life-alt]+ &
 lifesav+ treatm5ts c be *all5g+ =      
individuals ) a r>e disease or disord] &

 _! families2 ,:]eas individuals ) r>e  
diseases or disord]s c exp]i5ce         
difficulty 9 obta9+ accurate diagnoses &
 f9d+ physicians or treatm5t c5t]s )    
exp]tise 9 _! r>e disease or disord]2   
,:]eas1 al?\gh !re h be5 great          
advancem5ts 9 f9d+ treatm5ts = r>e      
diseases1 approximately #ie p]c5t ( r>e 
diseases /ill d n h a treatm5t approv$  
by ! ,,fda2 ,:]eas #bjbf m>ks ! #dcrd   
anniv]s>y ( ! enactm5t ( ! ,orphan ,drug
 ,act 7,public ,law #ig-dad2 #if ,/at4  
#bjdi71 a l&m>k law enabl+ trem5d\s     
advances 9 ! rese>* & treatm5t ( r>e    
diseases & disord]s2 ,:]eas ! ,national 
,in/itutes ( ,heal? support innovative  
rese>* on ! treatm5t ( r>e diseases &   
disord]s2 ,:]eas programs su* z !       
,accel]at+ ,r>e disease ,cures ,program 
( ! ,food & ,drug ,adm9i/ration 7ref]r$ 
to 9 ?is preamble z ! ,,fda7 aim to     
drive sci5tific & regulatory innovation 
& engagem5t to accel]ate ! availability 
( treatm5ts = pati5ts ) r>e diseases2   
,:]eas #bc ( ! #df novel drugs approv$  

by ! ,c5t] = ,drug ,evaluation & ,rese>*
 ( ! ,,fda 9 #bjbe-- 7#a7 7 approv$ to  
prev5t1 diagnose1 or treat a r>e disease
 or condition2 &  7#b7 receiv$ an       
orphan-drug designation2 ,:]eas ,r>e    
,disease ,day is obs]v$ ea* ye> on ! la/
 day ( ,febru>y2 & ,:]eas ,r>e ,disease 
,day is a global ev5t t 0 fir/ obs]v$ 9 
! ,unit$ ,/ates on ,febru>y #bh1 #bjji3 
,n[1 !re=e1 be x ,t ! ,s5ate-- 7#a7     
designates ,febru>y #bh1 #bjbf1 z ,r>e  
,disease ,day2 &  7#b7 recognizes !     
importance (1 ) respect to r>e diseases 
& disord]s-- 7,a7 improv+ aw>5ess2  7,b7
 enc\rag+ accurate & e>ly diagnosis2 &  
7,c7 support+ national & global rese>*  
ef=ts to develop effective treatm5ts1   
diagno/ics1 & cures4